Xgeva

Amgen vs. Sandoz: Legal Battle Erupts Over Bone-Strengthening Drug Patents
Amgen vs. Sandoz: Legal Battle Erupts Over Bone-Strengthening Drug Patents
Yahoo/Benzinga
Amgen
Sandoz
legal
Prolia
Xgeva
patents
denosumab
Flag link:
Amgen's denosumab shows promise in small, NIH-funded rare bone disease study
Amgen's denosumab shows promise in small, NIH-funded rare bone disease study
Endpoints
Amgen
Prolia
Xgeva
denosumab
clinical trials
NIH
biosimilars
monoclonal antibodies
Flag link:
Sandoz files biosimilar of Amgen osteoporosis drug in US
Sandoz files biosimilar of Amgen osteoporosis drug in US
Pharmaphorum
Sandoz
Novartis
biosimilars
osteoporosis
Prolia
Xgeva
FDA
Flag link:
The top 15 blockbuster patent expirations coming this decade
The top 15 blockbuster patent expirations coming this decade
Fierce Pharma
patents
patent cliff
AbbVie
Humira
Merck
Keytruda
Bristol Myers Squibb
Revlimid
Pfizer
Eliquis
Regeneron
Eylea
JNJ
Stelara
Opdivo
GSK
Dolutegravir
Ibrance
Januvia
Eli Lilly
Trulicity
Novo Nordisk
Victoza
Amgen
Prolia
Xgeva
Novartis
Cosentyx
Takeda
Entyvio
Flag link:
Could Amgen's Xgeva boost immunotherapy in breast cancer?
Could Amgen's Xgeva boost immunotherapy in breast cancer?
Fierce Biotech
Amgen
Xgeva
breast cancer
Flag link:
Sandoz recruits first patient in clinical study for proposed biosimilar denosumab in osteoporosis
Sandoz recruits first patient in clinical study for proposed biosimilar denosumab in osteoporosis
Pharmaceutical Business Review
Novartis
Sandoz
biosimilars
clinical trials
denosumab
osteoporosis
Prolia
Xgeva
Flag link:
Amgen focuses on migraine launch as growth remains slow
Amgen focuses on migraine launch as growth remains slow
Biopharma Dive
Amgen
earnings
Repatha
Kyprolis
Prolia
Xgeva
Flag link:
FDA expands use of Amgen's blockbuster drug
FDA expands use of Amgen's blockbuster drug
Yahoo/Reuters
FDA
Amgen
Xgeva
Multiple Myeloma
Flag link:
Amgen Files Marketing Applications to Expand Xgeva's Use to US and EU MM Patients
Amgen Files Marketing Applications to Expand Xgeva's Use to US and EU MM Patients
Yahoo/GuruFocus
Amgen
Xgeva
Multiple Myeloma
Europe
Flag link:
Dr Reddy's and Amgen broaden marketing collaboration
Dr Reddy's and Amgen broaden marketing collaboration
BioPharma Dive
Amgen
Dr Reddy's
India
Xgeva
Prolia
Vectibix
Flag link:
Amgen’s Bone Health Drug Saw Strong Revenue Growth in 2Q16
Amgen’s Bone Health Drug Saw Strong Revenue Growth in 2Q16
Market Realist
Amgen
Prolia
Xgeva
osteoporosis
Flag link:
Amgen reacquires rights to three drugs from Glaxo in 48 countries
Amgen reacquires rights to three drugs from Glaxo in 48 countries
Yahoo/Reuters
Amgen
GSK
Prolia
Vectibix
Xgeva
Flag link:
Amgen's bone drug Xgeva gets new approval
Amgen's bone drug Xgeva gets new approval
Yahoo/AP
Amgen
Xgeva
hypercalcemia of malignancy
Flag link:
Xgeva and Prolia: Setting the Pace for Amgen, Inc.
Xgeva and Prolia: Setting the Pace for Amgen, Inc.
Motley Fool
Xgeva
Prolia
Amgen
Flag link:
FDA approves new use for Amgen drug Xgeva, for rare type of bone tumors seen in young adults
FDA approves new use for Amgen drug Xgeva, for rare type of bone tumors seen in young adults
Yahoo/AP
Xgeva
FDA
Amgen
Flag link:
Anemic Growth? Not From These Drugs.
Anemic Growth? Not From These Drugs.
Motley Fool
Amgen
Affymax
Takeda
Epogen
Aranesp
Pfizer
Abbott Laboratories
JNJ
Novartis
Zometa
Xgeva
Prolia
Flag link:
FDA rejects Amgen's application for Xgeva
FDA rejects Amgen's application for Xgeva
Reuters
FDA
Amgen
prostate cancer
Xgeva
Flag link:
A Picture is Worth a Thousand Words: The Difference Between "Yes" and "No" During an FDA Advisory Committee
A Picture is Worth a Thousand Words: The Difference Between "Yes" and "No" During an FDA Advisory Committee
Elsevier Business
FDA
advisory panels
Xgeva
Amgen
Vivus
Qnexa
Flag link:
FDA panel votes against Xgeva for prostate cancer
FDA panel votes against Xgeva for prostate cancer
Yahoo/AP
prostate cancer
Xgeva
FDA
Amgen
Flag link:
Can Amgen Convince Docs to Recommend Xgeva Approval?
Can Amgen Convince Docs to Recommend Xgeva Approval?
Motley Fool
Amgen
Xgeva
physicians
prostate cancer
FDA
Flag link:

Pages